Cargando…
ABT-737 synergizes with Bortezomib to kill melanoma cells
The BH3 mimetic ABT-737 is a potent inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L), and Bcl-w. The Bcl-2 family modulates sensitivity to anticancer drugs in many cancers, including melanomas. In this study, we examined whether ABT-737 is effective in killing melanoma cells either alone or...
Autores principales: | Reuland, Steven N., Goldstein, Nathaniel B., Partyka, Katie A., Smith, Shilo, Luo, Yuchun, Fujita, Mayumi, Gonzalez, Rene, Lewis, Karl, Norris, David A., Shellman, Yiqun G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507205/ https://www.ncbi.nlm.nih.gov/pubmed/23213401 http://dx.doi.org/10.1242/bio.2011035 |
Ejemplares similares
-
The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
por: Reuland, Steven N., et al.
Publicado: (2011) -
MicroRNA-26a is Strongly Down-regulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD)
por: Reuland, Steven N., et al.
Publicado: (2012) -
Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
por: Mukherjee, Nabanita, et al.
Publicado: (2015) -
Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells
por: Mukherjee, Nabanita, et al.
Publicado: (2014) -
ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
por: Kim, Eun Young, et al.
Publicado: (2017)